Definitive Analysis
Definitive Analysis
Financial Statements
Periods / Units
Fundamentals
Valuations
Miscellaneous
Analysis Mode
Full Access
See Pricing Start Trial

China Resources Pharmaceutical Group Limited

Intrinsic Value Analysis (Discounted Cash Flow)Industry: Drug Manufacturers - Specialty & GenericSector: Healthcare

Fair Value Summary

Current Price$4.61
5Y Range31.88 – 67.47
5Y Selected49.67
(-) Safety Margin61.47%
5Y Buy Price$20.71
Upside (to Buy Price)349.23%
10Y Range36.64 – 75.67
10Y Selected56.15
(-) Safety Margin61.47%
10Y Buy Price$23.41
Upside (to Buy Price)407.83%

Company Predictability & Safety

MetricValue
Revenue R2 (5Y)0.9086
Revenue R2 (10Y)0.9767
Net Income R2 (5Y)0.7631
Net Income R2 (10Y)0.1874
EBITDA R2 (5Y)0.6999
EBITDA R2 (10Y)0.8087
FCF R2 (5Y)0.9147
FCF R2 (10Y)0.7170
Safety Score0.4169

DA 10-Year Projection

Metric2025202620272028202920302031203220332034
% Growth6.49%6.22%5.94%5.66%5.38%5.11%4.83%4.55%4.28%4.00%
Revenue291,984.46310,133.56328,551.78347,153.83365,847.58384,534.66403,111.20421,468.66439,494.76457,074.55
EBITDA17,947.1619,062.7220,194.8221,338.2122,487.2523,635.8724,777.7025,906.0627,014.0528,094.62
D&A-2,731.33-2,901.11-3,073.40-3,247.41-3,422.28-3,597.08-3,770.86-3,942.58-4,111.20-4,275.65
EBIT15,215.8316,161.6117,121.4218,090.8019,064.9720,038.7821,006.8421,963.4822,902.8523,818.97
Pro forma Taxes-3,317.45-3,523.65-3,732.92-3,944.27-4,156.66-4,368.98-4,580.04-4,788.61-4,993.42-5,193.16
NOPAT11,898.3812,637.9613,388.5014,146.5314,908.3115,669.8016,426.8017,174.8717,909.4318,625.81
Capital Expenditures-3,227.36-3,427.96-3,631.54-3,837.16-4,043.78-4,250.33-4,455.66-4,658.57-4,857.82-5,052.13
NWC Investment-2,439.25-2,486.81-2,523.69-2,548.87-2,561.44-2,560.53-2,545.38-2,515.36-2,469.96-2,408.80
(+) D&A2,731.332,901.113,073.403,247.413,422.283,597.083,770.863,942.584,111.204,275.65
Free Cash Flow8,963.119,624.2910,306.6711,007.9211,725.3612,456.0313,196.6113,943.5214,692.8615,440.53
Diluted Shares Outstanding6,282,510,000.006,282,510,000.006,282,510,000.006,282,510,000.006,282,510,000.006,282,510,000.006,282,510,000.006,282,510,000.006,282,510,000.006,282,510,000.00

Discounting Periods

MetricDec-25Dec-26Dec-27Dec-28Dec-29Dec-30Dec-31Dec-32Dec-33Dec-34
Period Start6/30/251/1/261/1/271/1/281/1/291/1/301/1/311/1/321/1/331/1/34
Period End12/31/2512/31/2612/31/2712/31/2812/31/2912/31/3012/31/3112/31/3212/31/3312/31/34
Mid-Point9/30/257/2/267/2/277/1/287/2/297/2/307/2/317/1/327/2/337/2/34
Time (t)0.100.461.462.463.464.465.466.467.468.46
Valuation Date1/16/26

Base Case Projected Flows

WACC: 6.53%Terminal Growth: 2.49%
Metric2025202620272028202920302031203220332034TV (5y)TV (10y)
Discount Factor0.990.970.910.860.800.750.710.660.620.59
PV UFCF8,906.609,348.349,397.629,421.909,420.939,394.669,343.259,267.059,166.639,042.72
Raw: 297,438.06
231,542.59
Raw: 391,680.80
222,247.20

Base Case Valuation

5-Year Horizon10-Year Horizon
UFCFUFCF
Enterprise Value278,037.99314,956.89
(-) Net Debt7,463.687,463.68
Equity Value270,574.30307,493.21
(/) Shares Out6,282.516,282.51
Fair Value$43.07$48.94
(-) Safety Margin61.47%61.47%
Buy Price$16.59$18.86
Current Price$4.61$4.61
Upside (to Buy Price)259.96%309.07%

Conservative Projected Flows

WACC: 7.53%Terminal Growth: 1.99%
Metric2025202620272028202920302031203220332034TV (5y)TV (10y)
Discount Factor0.990.970.900.840.780.720.670.630.580.54
PV UFCF8,898.299,308.249,270.309,207.819,121.249,011.218,878.568,724.258,549.468,355.46
Raw: 215,849.19
161,925.78
Raw: 284,240.64
148,331.20

Conservative Valuation

5-Year Horizon10-Year Horizon
UFCFUFCF
Enterprise Value207,731.65237,656.02
(-) Net Debt7,463.687,463.68
Equity Value200,267.97230,192.34
(/) Shares Out6,282.516,282.51
Fair Value$31.88$36.64
(-) Safety Margin61.47%61.47%
Buy Price$12.28$14.12
Current Price$4.61$4.61
Upside (to Buy Price)166.43%206.24%

Aggressive Projected Flows

WACC: 5.53%Terminal Growth: 2.99%
Metric2025202620272028202920302031203220332034TV (5y)TV (10y)
Discount Factor0.990.980.920.880.830.790.750.710.670.63
PV UFCF8,915.019,388.989,527.929,643.069,733.439,798.279,836.999,849.229,834.819,793.81
Raw: 475,383.63
384,148.30
Raw: 626,008.13
386,531.18

Aggressive Valuation

5-Year Horizon10-Year Horizon
UFCFUFCF
Enterprise Value431,356.71482,852.69
(-) Net Debt7,463.687,463.68
Equity Value423,893.02475,389.01
(/) Shares Out6,282.516,282.51
Fair Value$67.47$75.67
(-) Safety Margin61.47%61.47%
Buy Price$26.00$29.16
Current Price$4.61$4.61
Upside (to Buy Price)463.92%532.43%

Reverse DCF: Market Implied Growth

Current Price$4.61
WACC Used6.5%
IMPLIED REVENUE GROWTH46.39%
Metric2027202820292030203120322033203420352036
Implied Revenue812,860.141,189,919.281,741,883.792,549,886.533,732,695.235,464,170.067,998,819.2611,709,209.0517,140,726.9225,091,747.71
Constant Implied Growth46.39%46.39%46.39%46.39%46.39%46.39%46.39%46.39%46.39%46.39%
Implied Free Cash Flow81.29118.99174.19254.99373.27546.42799.881,170.921,714.072,509.17
Discount Factor0.960.860.800.750.710.660.620.590.550.52
Present Value of Implied FCF77.77101.85139.95192.32264.28363.16499.03685.75942.321,294.90

Rolling Historical DCF (Backtest)

Valuation based on actual realized growth.
YearValuation DateActual PriceRealized Growth (5Y)Calculated Fair ValueValuation Delta
20192019-12-31$7.237.60%$4.74-34.47%
20182018-12-31$10.227.97%$15.3349.96%
20172017-12-31$10.127.33%$5.31-47.48%
20162016-12-31$8.756.89%$4.65-46.85%
20152015-12-31$9.011.70%$6.98-22.58%
20142014-12-31$9.01-0.01%$-1.92-121.29%
20132013-12-31$9.014.91%$0.74-91.75%

Monte Carlo Simulation (1,000 Iterations)

Mean Fair Value
$54.76
Median
$49.83
10th Percentile
$36.36
90th Percentile
$77.91

Fair Value Distribution

$27.75 - $37.24
122
$37.24 - $46.72
297
$46.72 - $56.21
243
$56.21 - $65.69
140
$65.69 - $75.18
81
$75.18 - $84.67
42
$84.67 - $94.15
31
$94.15 - $103.64
13
$103.64 - $113.12
8
$113.12 - $122.61
6
$122.61 - $132.09
5
$132.09 - $141.58
3
$141.58 - $151.07
2
$151.07 - $160.55
2
$160.55 - $170.04
2
$170.04 - $179.52
0
$179.52 - $189.01
1
$189.01 - $198.49
0
$198.49 - $207.98
0
$207.98 - $217.46
1